« Previous | Contents | Next »
Listen
REFERENCES
1. Scottish Executive Health Department. The Right
Medicine: A Strategy for Pharmaceutical Care in Scotland.
Astron, Edinburgh: 2002.
2. Public Health Institute of Scotland. Pharmacy for
Health: The Way Forward for Pharmaceutical Public Health in
Scotland.
PHIS, Glasgow: 2002.
3. Scottish Executive. Modernising
NHS Community Pharmacy in Scotland: A
Consultation Paper. Astron, Edinburgh: 2004.
4. Home Office. Hidden Harm: Responding to the Needs of
Children of Problem Drug Users. A Report of an Inquiry by
the Advisory Council on the Misuse of Drugs. London:
2003.
5. Interim Report of the Scottish Schools Adolescent
Lifestyle and Substance Use Survey (
SALSUS), 2004.
6. Hay G, Gannon M, McKeganey N, Hutchinson S, Goldberg
D. Estimating the National and Local Prevalence of Problem
Drug Misuse in Scotland. Executive Report. University of
Glasgow and Scottish Centre for Infection and Environmental
Health, Glasgow, 2005.
7. Scottish Executive Justice Department.
HM Chief Inspector of Prisons for
Scotland. Report for 1999-2000. The Stationery Office,
Edinburgh. Cm 4824.
8. Scottish Executive Health Department/Know the Score:
Volatile Substance Abuse. Astron, Edinburgh: 2003.
9. Scottish Executive Health Department. Health in
Scotland 2002. Astron, Edinburgh: 2002.
10. The General Register Office for Scotland. Registrar
General for Scotland 2002. Vital Events Preliminary Return:
Table P1. Population and Vital Events, Scotland, 1855-2002.
Edinburgh, 2003.
11.
NHS Health Scotland/
ASH Scotland. Reducing Smoking and
Tobacco-related Harm: A Key to Transforming Scotland's
Health. Health Scotland, Edinburgh: 2003.
12. Drug Misuse Statistics Scotland, Edinburgh:
2003.
13. Guest J. What are the costs of alcohol problems for
hospitals in Scotland? [Paper prepared for conference
entitled "Do Hospitals Need Alcohol Liaison Nurses?".
Edinburgh, 14 February 2003].
14. Faraday M M, Elliott B M and Grunberg N E.
Nicotine's behavioural actions differ in adult versus
adolescent rats.
Nicotine and Tobacco Research 2002; 2: 292.
15. Weincke J K, Thurston S W, Kelsey K T, Varkonyi A,
Wain J C, Mark E J,
et al. Early age at smoking initiation and tobacco
carcinogen
DNA damage in the lung.
Journal of the National Cancer Institute.
1999.91:614-9.
16. Misuse of Drugs Act (1971).
HMSO, London.
17. Medicines Act (1968).
HMSO, London.
18. Scottish Specialists in Pharmaceutical Public Health
Group. [available on a website].
19. The Scottish Office. The Report of the Ministerial
Drugs Task Force: Drugs in Scotland: Meeting the Challenge.
HMSO, Edinburgh: 1994.
20. Hay G, McKeganey N, Hutchinson S. Estimating the
National and Local Prevalence of Problem Drug Misuse in
Scotland. Executive Report. University of Glasgow and
SCIEH, Glasgow, 2001, 5.1:9.
21. The Scottish Office. Tackling Drugs in Scotland:
Action in Partnership. The Stationery Office, Edinburgh:
1999.
22. The Scottish Executive Health Department. Drug
Action Plan: Protecting Our Future. Astron, Edinburgh:
2000.
23. Scottish Executive Health Department. Review of Drug
Treatment and Rehabilitation Services: Summary and Actions.
[On-line publication only] accessed at
http://www.scotland.gov.uk/library5/health/drugrehabreview.pdf
24. Scottish Executive. Drugs Action Plan: Protecting
Our Future. Astron, Edinburgh. 2000.
25. Scottish Executive Health Department. Getting Our
Priorities Right: Good Practice Guidelines. Astron,
Edinburgh: 2003.
26. Scottish Executive Health Department/
NHS Health Scotland/Scottish Drugs
Forum/Alcohol Focus Scotland: Alcohol: What Every Parent
Should Know. 2004
27. Scottish Executive Health Department. A Breath of
Fresh Air for Scotland. Improving Scotland's Health: The
Challenge. Tobacco Control Action Plan. Astron, Edinburgh:
2004.
28. Scottish Executive. Health in Scotland 2003. Astron,
Edinburgh. 2004
29. Buck D, Godfrey C, Parrott S, and Raw M. Cost
Effectiveness of Smoking Cessation Interventions. Health
Education Authority, London: 1997.
30. Parrott S, Godfrey C, and Raw, M. Costs of employee
smoking in the workplace in Scotland.
Tobacco Control 2000; 9: 187-192
31. Department of Health. Smoking Kills.
HMSO; London: 1998.
32. Scottish Executive. Smoking in Public Places: A
Consultation on Reducing Exposure to Second-hand Smoke.
Astron, Edinburgh. 2004
33. The Scottish Office. Towards a Healthier Scotland.
HMSO; Edinburgh: 1999.
34. Scottish Executive Health Department. Plan for
Action on Alcohol Problems. Astron, Edinburgh: 2002.
35. Scottish Executive Health Department. Alcohol
Problems Support and Treatment Services Framework. Astron,
Edinburgh: 2002.
36. Scottish Executive Health Department/
NHS Health Scotland/Scottish Drugs
Forum/Alcohol Focus Scotland: Drugs: What Every Parent
Should Know. 2004.
37. Scottish Executive. A Partnership for a Better
Scotland: Partnership Agreement. Astron, Edinburgh.
2004.
38. Shipman Inquiry [Fourth report]. The Regulation of
Controlled Drugs in the Community. Command Paper Cm 6249
[July 2004].
39. Shipman Inquiry [Fifth Report]. Safeguarding
Patients: Lessons from the Past - Proposals for the Future.
Command Paper Cm 6394 [December 2004].
40. Roberts K, McNulty H, Gruer L
et al. The role of Glasgow pharmacists in the
management of drug misuse.
International Journal on Drug Policy 1998. 9:
187-194.
41. Roberts K and Bryson S. The contribution of Glasgow
pharmacists to the management of drug misuse.
Hospital Pharmacist. 1999. 6: 244-248.
42. Walker M. Shared care for opiate substance misusers
in Berkshire.
The Pharmaceutical Journal 2001, 266: 547-550.
43. Matheson C. Illicit drug users views of a "good" and
"bad" pharmacy service.
Journal of Social and Administrative Pharmacy.
1998; 15(2):104-112.
44. Gruer L, Wilson P, Scott R, Elliott L, Macleod J,
Harden K, Forrester E, Hinshelwood S, McNulty H, Silk P.
General practitioner centred scheme for treatment of opiate
dependent drug injectors in Glasgow.
British Medical Journal. 1997; 314:1730-1735.
45. Royal Pharmaceutical Society of Great Britain.
Council Guidance. Guidelines for pharmacists involved in
schemes to supply clean syringes and needles to addicts.
Pharmaceutical Journal 1987; 231: 481.
46. Royal Pharmaceutical Society of Great Britain.
Council Guidance. Guidelines for pharmacists involved in
schemes to supply clean syringes and needles to addicts.
Pharmaceutical Journal 1989; 242: 176.
47. Royal Pharmaceutical Society of Great Britain.
Council Guidance. Needle and syringe supply.
Pharmaceutical Journal. 1991; 246: 488.
48. Royal Pharmaceutical Society of Great Britain.
Council Guidance. Needle and syringe supply.
Pharmaceutical Journal 1993; 251: 20.
49. National Pharmaceutical Association. Syringe and
Needle Exchange Resource Pack.
NPA, 1998.
50. Scottish Needs Assessment Programme (
SNAP) Hepatitis C. Office for Public
Health in Scotland; Glasgow: 2000.
51. Scottish Executive Health Department. Report of the
HIV Health Promotion Strategy Review
Group. Astron, Edinburgh: 2001.
52. Misuse of Drugs (Amendment) (No 2) Regulations
2003.
53. Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin
overdose: the case for take-home naloxone?
British Medical Journal 1996; 312: 1435.
54. Darke S, Hall W. The distribution of naloxone to
heroin users.
Addiction 1997; 92: 1195-1199.
55. Strang J. Take-home naloxone: the next steps.
Addiction 1999; 94: 207.
56. Strang J, Powis B, Best D, Vingoe L, Griffiths P,
Taylor C,
et al. preventing opiate overdose fatalities with
take-home naloxone: pre-launch study of possible impact and
acceptability.
Addiction 1999; 94: 199-204.
57. Dettmer, K, Saunders B, Strang J. Take-home naloxone
and the prevention of deaths from opiate overdose: two
pilot schemes.
British Medical Journal 2001; 322: 895-896.
58. Sporer K A. Strategies for preventing heroin
overdose.
British Medical Journal 2003; 326:442-444.
59. Roberts, K. - Personal communication.
60. Royal Pharmaceutical Society of Great Britain.
Medicines, Ethics and Practice: A Guide for Pharmacists.
RPSGB; London: 2004.
61. Matheson C, Bond C M, Pitcairn J. Misuse of
over-the-counter medicines from community pharmacies: A
population survey of Scottish pharmacies.
The Pharmaceutical Journal 2002, 269: 66-68.
62. Downie G, Hind C, Kettle J. The abuse and misuse of
prescribed and over-the-counter medicines.
Hospital Pharmacist 2000, 7:242-250.
63. Pates R, McBride A, Li S, Ramadan R. Misuse of
over-the-counter medicines: A survey of community
pharmacies in a South Wales Health Authority.
The Pharmaceutical Journal 2002, 268: 179-182.
64. Department of Health.
NHS Plan: A Plan for Investment, A Plan
for Reform. The Stationery Office; London: 2000.
65. West R, McNeill A, and Raw M. Smoking cessation
guidelines for health professionals: an update.
Thorax. 2000; 55: 987-999.
66. National Institute for Clinical Excellence (
NICE). The Use of Nicotine Replacement
Therapy (
NRT) and Buproprion for Smoking
Cessation. Technology Appraisal Guidance No.39.
NICE; London: 2002.
67. Turner S. An overview of the success of smoking
cessation programmes.
Community Pharmacy 2002; February: 30-31.
68. Rogotti N A, Munafo M R, Murphy M F G, and Stead L
F. Interventions for Smoking Cessation in Hospitalised
Patients (Cochrane Review). Issue 4. Update Software,
Oxford: 2002. The Cochrane Library.
69. Wills S. Excessive alcohol problems. In: Harman RJ
(Ed). Handbook of Pharmacy Health Education (2nd Edition).
Pharmaceutical Press. London: 2001.
70. Mason P. Alcohol Misuse - A Case Study.
The Pharmaceutical Journal. 2003.271: 777-779.
71. Slattery J, Chick J, Cochrane M,
et al. Prevention of relapse in alcohol
dependence. (Health Technology Assessment Report 3). Health
Technology Board for Scotland, Glasgow, 2003.
72. Misuse of Drugs Regulations (2001) and amendments.
Home Office.
HMSO; London.
73. Bellingham C. Shipman Inquiry: impact on pharmacy.
The Pharmaceutical Journal. 2004.272: 81-82.
74. Data Protection Act (1998).
HMSO, London.
75. Human Rights Act (1998).
76. An independent inquiry arising from the Soham
murders. (Chairman:, Sir Michael Bichard).
HC 653. The Stationery Office, London
(22 June 2004).
77. Children (Scotland) Act 1995.
HMSO; Edinburgh.
78. Convention on the Rights of the Child.
UN General Assembly, 1989.
79. Age of Legal Capacity (Scotland) Act (1991).
HMSO; Edinburgh.
80. Scottish Executive. Effective Interventions
Unit/Partnership Drugs Initiative, Lloyds
TSB Foundation for Scotland. Services
for Young People with Problematic Drug Misuse: A Guide to
Principles and Practice. Astron; Edinburgh: 2002.
81. Scottish Executive. Effective Interventions Unit.
Young People with, or at Risk of Developing, problematic
Substance Misuse: A Guide to Assessment. Astron. Edinburgh:
2004.
82. Scottish Executive Health Department.
HDL (2002) 90 Needle and Syringe
Exchange Schemes [issued 19 December 2002].
83. Scottish Drugs Forum - Personal communication.
84. Information and Statistics Division (now Information
Services) - Prescribing Information System.
85. Roberts K, Hunter C. A comprehensive system of
pharmaceutical care for drug misusers.
Harm Reduction Journal 2004; 1:6.
86. Parr R M (ed). Pharmaceutical Care of the Drug
Misuser. Scottish Centre for Post Qualification Education.
Glasgow: 1999.
87. Parr (ed) Pharmaceutical aspects of methadone
prescribing. 1996 reprinted 1998 and 2000. Scottish Centre
for Post Qualification Pharmaceutical Education. Glasgow
2001.
88. Scottish Specialists in Pharmaceutical Public
Health. Toolkit for Assessing the Pharmaceutical Needs of
Populations: Out of Hours Pharmaceutical Services.
2003.
89. Social Inclusion, Housing and Voluntary Sector
Committee. Sixth Inquiry into Drug Misuse and Deprived
Communities. Edinburgh: 2000.
90. Social Work Services Inspectorate (
SWSI). The Report of a Review of the
Rough Sleepers Initiative in Glasgow. Scottish Executive;
Edinburgh: 2001.
91. Neale J, McKeganey N. Drug Users' Risk Behaviour in
Relation to Non-fatal Overdose: A Qualitative Study of
Accident and Emergency Admissions with Matched Controls.
Final Report submitted to the Scottish Executive Health
Department.
92. Law and Ethics Bulletin. Supply to wrong patient.
Pharmaceutical Journal 1997; 259:599.
93. Roberts K. Legal Considerations for Community
Pharmacists in the United Kingdom [Ch 9] In: Sheridan J and
Strang J [eds]. Drug Misuse and Community Pharmacy. Taylor
and Francis. London and New York. 2003.
94. Royal Pharmaceutical Society of Great Britain.
Pharmaceutical Services to Drug Misusers.
RPSGB, London. 1998.
95. Gossop M, Marsden J, Stewart D, Lehmann P, Edwards
C, Wilson A, Segar G. Substance use, health and social
problems of clients at 54 drug treatment agencies: intake
data from the National Treatment Outcome Research Study (
NTORS).
British Journal of Psychiatry. 1998: 173:
166-171.
96. McIntosh J, McKeganey N. Identity and recovery from
dependent drug use: the addict's perspective.
Drugs Education, Prevention and Policy. 2001;
8(1): 47-59.
97. Hepler C D, Strand L M. Opportunities and
responsibilities in pharmaceutical care.
American Journal of Hospital Pharmacy 1990; 47:
533-543.
98. Clinical Resources and Audit Group (
CRAG). Framework for Clinical Pharmacy
Practice in Primary Care.
99. Scottish Executive.
MEL (1999)78. Community Pharmacy: Model
Schemes for Pharmaceutical Care. [Issued 9 November
1999].
« Previous | Contents | Next »